To achieve long-term Depression remission, patients need a treatment plan that controls their symptoms as fully as possible. Studies have shown that 76% of patients who still have residual symptoms after treatment for Depression relapse early. However, among patients whose symptoms are reduced to minimal levels, only 25% relapse.
Antidepressant medications are a key part of treating Depression, but they do not work for everyone. The Institute for Quality and Efficiency in Health Care (IQWiG) states that the main aim of antidepressant treatment is “to relieve the symptoms of severe [D]epression, such as feeling very down and exhausted, and prevent them from coming back,” and notes that some people still have symptoms after trying several different medications.
For these patients, TMS can lead to remission, and TMS maintenance treatments can help preserve long-term Depression remission.
A newly published study in the journal Transcranial Magnetic Stimulation now provides new evidence regarding the long-term effectiveness of repetitive transcranial magnetic stimulation (rTMS, referred to below as TMS) compared to antidepressant medication in patients with treatment-resistant Depression. The study followed patients for an entire year after randomized treatment. It helps answer the central question about TMS long-term success: can the benefits last?
Key Points at a Glance
- In a 2026 study, people with hard-to-treat Depression were randomly assigned to TMS or a change in their medication. After eight weeks, more people improved with TMS (about 41% compared with about 19%).
- Among people treated with TMS who kept attending check-ins, the share who were doing well stayed about the same for a full year.
- Five of the six early TMS responders checked at one year were still doing well, and only one of them needed a short booster of TMS.
- The medication group partly caught up over time, but 69% of that group went on to receive TMS during the follow-up year.
- The study was small, and many people stopped attending check-ins, so the results are encouraging but not final. The TMS course was also shorter than what is now considered typical.
A New 12-Month Study on TMS Long-Term Success vs. Antidepressants
The new study by Dalhuisen and colleagues, a research team in the Netherlands, examined twelve-month outcomes following randomized treatment with either rTMS plus psychotherapy or antidepressant pharmacotherapy plus psychotherapy.
Study Design
The study followed patients who had previously participated in an eight-week randomized controlled trial comparing TMS to guideline-based antidepressant treatment.
Researchers included adults with:
- Unipolar Depression without psychotic features
- Moderate to severe depressive symptoms
- Hamilton Depression Rating Scale (HDRS-17) scores greater than 16
- At least two failed treatment trials, including at least one antidepressant trial of adequate dose and duration
Current depressive episodes had to be less than two years in duration. Of 89 patients randomized, a total of 76 completed the eight-week trial and were followed: 44 in the TMS group and 32 in the medication group.
Patients in the medication group received the next step under Dutch guidelines for treatment-resistant Depression, such as switching to a tricyclic antidepressant or adding lithium or a second-generation antipsychotic. Both groups also received supporting psychotherapy sessions during the eight-week treatment phase.
TMS Protocol
Patients assigned to TMS received:
- 25 sessions
- High-frequency 10 Hz stimulation
- 3000 pulses per session
- 120% resting motor threshold
- Left dorsolateral prefrontal cortex (DLPFC) targeting
This is a standard approach for FDA-cleared TMS. For an explanation of how stimulation works, see How Does TMS Work?
How Fast Does TMS Work?
Patients often ask, “How fast does TMS work?” The protocol behind the initial FDA clearance of TMS used daily sessions, five days a week, for up to six weeks. In the new study, patients received 25 sessions over eight weeks, and outcomes were first measured at the end of that period. Three TMS patients who had not responded by week eight reported a delayed response in the months after treatment ended. For more on how session counts affect results, see How Many Sessions for TMS to Work?
TMS Therapy Success Rates After Eight Weeks
At the end of the initial eight-week treatment period, TMS outperformed medication. These were the TMS therapy success rates at the end of treatment:
- TMS group: 40.9% response and 29.5% remission
- Medication group: 18.8% response and 6.3% remission
Response was defined as at least a 50% reduction in HDRS-17 scores. Remission was defined as a score below 8, indicating minimal depressive symptoms.
These findings are clinically meaningful because remission, not simply partial improvement, is associated with better overall mental health and quality of life, as well as lower relapse rates. For more on this distinction, see Remission in Depression.
TMS Remission and Response Over Twelve Months
According to the study authors, both response and remission rates in the TMS group then remained relatively stable throughout the twelve-month follow-up period. The TMS long-term results at each follow-up point are below.
TMS Response Rates Over Time
- End of treatment: 40.9%
- 4 months: 40.5%
- 6 months: 45.5%
- 9 months: 44.8%
- 12 months: 36%
TMS Remission Rates Over Time
- End of treatment: 29.5%
- 4 months: 32.4%
- 6 months: 30.3%
- 9 months: 34.5%
- 12 months: 32%
Although there was some fluctuation over time, the overall pattern was consistent with sustained benefit. This is especially important because treatment-resistant Depression is frequently characterized by relapse and symptom recurrence. For patients weighing TMS long-term success against another medication trial, stability over a full year is a meaningful signal.
Among TMS responders with twelve-month data, five of six maintained their improvement. Three of those five received no additional treatment, one received a five-session TMS booster at four months, and one stopped psychotropic medication and remained stable. Three of four patients in TMS remission with twelve-month data remained in remission.
The TMS group also showed reductions in anxiety and anhedonia between baseline and the end of treatment, while the medication group did not. Both groups showed a small decrease in rumination, and these scores remained largely stable at six and twelve months.
Why the Medication Group Narrowed the Gap
The medication group showed a different pattern. At the end of acute treatment, outcomes were substantially lower than in the TMS group. However, both response and remission rates improved by four months before stabilizing.
Medication Response Rates
- End of treatment: 18.8%
- 4 months: 33.3%
- 6 months: 35.7%
- 9 months: 36.4%
- 12 months: 43.6%
Medication Remission Rates
- End of treatment: 6.3%
- 4 months: 20%
- 6 months: 17.8%
- 9 months: 22.7%
- 12 months: 25%
At first glance, these later improvements may appear to narrow the gap between the groups. However, the explanation is highly important. As the study authors report:
- 69% of patients originally assigned to medication received TMS at some point during follow-up
- Four of the six medication patients who later became responders had received TMS during the naturalistic follow-up period
This crossover substantially complicates direct long-term comparison between groups. Importantly, it also reflects real-world clinical practice. Many patients who do not respond to antidepressants continue searching for effective treatment options and go on to pursue TMS.
Strengths and Limitations of the Study
The original trial randomized patients to treatment groups, helping reduce selection bias, and the naturalistic “treatment as usual” follow-up closely reflects actual psychiatric practice. The study also focused on patients who had already failed at least two prior treatments, making the findings especially relevant for real-world TMS candidates.
The authors appropriately emphasized several limitations. By twelve months, the TMS group had lost 43.2% of participants and the medication group had lost 50%, and patients doing poorly may have been less likely to continue follow-up. The crossover to TMS blurred the comparison between groups. The sustained-response figures rest on small numbers of patients. Finally, patients received only 25 TMS sessions, which the authors describe as relatively limited, and suggest that more sessions might have produced more pronounced and sustained effects.
How These Findings Fit With Earlier Research on TMS Long-Term Success
The theories that form the basis of TMS therapy have been developed over many years, and TMS has been FDA-cleared for Depression since 2008. Clinicians now draw on a large body of literature to measure the durability of response after TMS, and the new data add to earlier findings.
What If Depression Returns? Preventing Relapse Post-TMS
Some patients notice symptoms returning months after a course of TMS. In the new study, only one patient received a booster (five sessions at four months), and the authors call for research comparing fixed-interval and symptom-triggered maintenance.
Long-Term Depression Remission Through Follow-Up TMS Sessions
TMS maintenance sessions are a valuable option for preventing relapse post-TMS, particularly if you have previously benefited from an acute TMS treatment plan and are now experiencing a return of Depression symptoms. In the Senova meta-analysis, sustained response was higher among patients who received maintenance TMS than among those who did not, at both three and six months.
A multisite clinical trial of 301 patients also examined TMS as a tool for long-term Depression remission. Patients who improved during the acute trial (99 in the analysis) were tapered off TMS, started on maintenance antidepressant medication, and followed for 24 weeks. Only 10% relapsed. Of the 38 patients whose symptoms worsened, 32 (84.2%) improved again with additional TMS, with safety and tolerability similar to acute treatment. These results show that TMS can be used intermittently as a maintenance treatment option. However, it’s worth noting that patients entered this phase after at least partial response (more than a 25% reduction in symptoms), all patients took antidepressant medication, and there was no comparison group during follow-up.
Mid City TMS covers maintenance options in more depth in What Is TMS Maintenance? and Maintenance TMS for Depression.
Long-Term Depression Remission at Mid City TMS
For patients struggling with treatment-resistant Depression, this study offers encouraging news about TMS long-term success. The findings suggest that:
- TMS can produce meaningful improvement
- Benefits may persist for many months
- Some patients maintain remission for a full year after treatment ends
- TMS may improve difficult symptoms such as anxiety and anhedonia
- Durability may occur even with relatively limited treatment courses
At Mid City TMS, we frequently see patients who have spent years cycling through medications with limited success or intolerable side effects. Studies like this reinforce the growing evidence that TMS is not simply a short-term intervention, but may provide durable, sustained improvement for many individuals with treatment-resistant Depression.
As one of the earliest providers of TMS therapy in the greater New York metropolitan area, Mid City TMS has built a legacy of championing effective Depression treatment. Our goal is to restore our patients’ health and happiness through TMS by helping our patients achieve remission. To accomplish this goal, we provide individualized maintenance TMS to preserve the durability of response after TMS therapy. We also offer Theta Burst TMS as a convenient and efficient option for boosting your TMS treatment.
Whether you are researching the response after TMS because you need a Depression treatment that can lead to remission, or you are seeking a follow-up to your acute TMS treatment, our dedicated team will craft an individualized treatment plan that meets your needs. Contact us today or call us today at 212-517-1867 to make an appointment.
Sources
- Dalhuisen, I., van Oostrom, I., Spijker, J., Wijnen, B., van Exel, E., van Mierlo, H., de Waardt, D., Arns, M., Tendolkar, I., & van Eijndhoven, P. Long-term outcomes following randomized rTMS or antidepressant treatment: A twelve-month naturalistic follow-up. Transcranial Magnetic Stimulation. 2026;7:100212. https://doi.org/10.1016/j.transm.2026.100212
- Rush University Medical Center. (n.d.). Psychiatry services. Rush University Medical Center. Retrieved from https://www.rush.edu/services/psychiatry
- Rush University Medical Center. (n.d.). Home page. Rush University Medical Center. Retrieved from https://www.rush.edu/
- George, M. S., & Belmaker, R. H. (2007). Transcranial magnetic stimulation for the treatment of depression. Archives of General Psychiatry, 67(5), 507-516. https://www.ncbi.nlm.nih.gov/pubmed/20965447/
- Wassermann, E. M., & Lisanby, S. H. (2001). Therapeutic application of repetitive transcranial magnetic stimulation: A review. Semantics Scholar. Retrieved from https://pdfs.semanticscholar.org/a52e/062f3ed9201840664c2f2486faf33361ef96.pdf
- Pascual-Leone, A., & Tormos, J. M. (2010). Transcranial magnetic stimulation in neuropsychiatry. TMS Lab Publications. Retrieved from http://www.tmslab.org/publications/845.pdf
- Sackeim, H. A., Lisanby, S. H., & Grunhaus, L. (1996). Motor threshold in transcranial magnetic stimulation: A comparison of different estimation methods. Biological Psychiatry, 39(9), 703-712. https://www.ncbi.nlm.nih.gov/pubmed/8637947
- McVoy, M., et al. (2016). Pharmacotherapy for child and adolescent depression. In D. G. Daniel (Ed.), Managing Child and Adolescent Depression: A Clinical Guide (pp. 1-16). National Center for Biotechnology Information (NCBI). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK361016/